Date published: 2026-4-1

1-800-457-3801

SCBT Portrait Logo
Seach Input

OCT2 Inhibitors

OCT2 inhibitors encompass a diverse set of compounds that act either directly or indirectly to modulate OCT2 activity by targeting specific pathways or cellular processes crucial for its regulation. Cimetidine, a H2 receptor antagonist, directly inhibits OCT2 by competing for substrate binding sites, thereby reducing the transport of cationic substrates by OCT2. Probenecid, a URAT1 inhibitor, indirectly influences OCT2 by reducing renal excretion, elevating systemic levels of substrates recognized by OCT2. Trimethoprim, an antibiotic, directly interferes with OCT2 transport activity, particularly impacting organic cation substrates. Dolutegravir, an integrase inhibitor, indirectly affects OCT2 by influencing the P-glycoprotein (P-gp) efflux pump, altering the disposition of drugs recognized by both P-gp and OCT2. Quinidine, an antiarrhythmic agent, directly inhibits OCT2 by competing for substrate binding sites, reducing the transport of cationic drugs. Verapamil, a calcium channel blocker, indirectly impacts OCT2 by inhibiting P-glycoprotein (P-gp), affecting the disposition of substrates recognized by both P-gp and OCT2. Famotidine, another H2 receptor antagonist, directly inhibits OCT2 by competing for binding sites, reducing the transport of cationic substrates. Pyrimethamine, an antiprotozoal agent, indirectly influences OCT2 by inhibiting P-glycoprotein (P-gp), affecting the disposition of drugs recognized by both P-gp and OCT2. Amiloride, a sodium channel blocker, indirectly affects OCT2 by inhibiting NHE3, a sodium-hydrogen exchanger, potentially altering the cellular environment and impacting OCT2 activity. Rifampin, an antibiotic, indirectly influences OCT2 by inducing the expression of efflux transporters, such as P-glycoprotein (P-gp). Minoxidil, a vasodilator, directly inhibits OCT2 by competing for substrate binding sites. Gemfibrozil, a PPARα agonist, indirectly modulates OCT2 activity by influencing the expression of organic anion transporters (OATs), which can impact the disposition of substrates recognized by both OATs and OCT2. In summary, OCT2 inhibitors present a versatile collection of compounds that offer potential strategies for precise modulation of OCT2 activity through direct and indirect mechanisms.

Items 1 to 10 of 12 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Cimetidine

51481-61-9sc-202996
sc-202996A
5 g
10 g
$62.00
$86.00
1
(1)

H2 receptor antagonist that inhibits OCT2 directly by competing for binding sites, reducing the transport of substrates recognized by OCT2.

Probenecid

57-66-9sc-202773
sc-202773A
sc-202773B
sc-202773C
1 g
5 g
25 g
100 g
$28.00
$39.00
$100.00
$277.00
28
(2)

URAT1 inhibitor indirectly influencing OCT2 by reducing renal excretion and subsequently elevating systemic levels of substrates for OCT2.

Trimethoprim

738-70-5sc-203302
sc-203302A
sc-203302B
sc-203302C
sc-203302D
5 g
25 g
250 g
1 kg
5 kg
$67.00
$161.00
$255.00
$721.00
$3401.00
4
(1)

Antibiotic inhibiting OCT2 by directly interfering with its transport activity, particularly impacting organic cation substrates.

S/GSK1349572

1051375-16-6sc-364605
sc-364605B
sc-364605A
5 mg
50 mg
200 mg
$374.00
$1514.00
$4214.00
(0)

Integrase inhibitor with an indirect impact on OCT2 by influencing the P-glycoprotein (P-gp) efflux pump, affecting the disposition of drugs recognized by both P-gp and OCT2.

Quinidine

56-54-2sc-212614
10 g
$104.00
3
(1)

Antiarrhythmic agent directly inhibiting OCT2 by competing for substrate binding sites, reducing the transport of cationic drugs by OCT2.

Verapamil

52-53-9sc-507373
1 g
$374.00
(0)

Calcium channel blocker impacting OCT2 indirectly by inhibiting the activity of P-glycoprotein (P-gp), a transporter that can affect the disposition of substrates recognized by both P-gp and OCT2.

Famotidine

76824-35-6sc-205691
sc-205691A
500 mg
1 g
$65.00
$111.00
(0)

H2 receptor antagonist inhibiting OCT2 directly by competing for binding sites, reducing the transport of cationic substrates by OCT2.

Pyrimethamine

58-14-0sc-208190
sc-208190A
sc-208190B
1 g
5 g
25 g
$80.00
$238.00
$825.00
5
(0)

Antiprotozoal agent with an indirect impact on OCT2 by inhibiting the P-glycoprotein (P-gp) efflux pump, affecting the disposition of drugs recognized by both P-gp and OCT2.

Amiloride

2609-46-3sc-337527
1 g
$296.00
7
(1)

Sodium channel blocker with an indirect effect on OCT2 by inhibiting the activity of NHE3, a sodium-hydrogen exchanger, altering the cellular environment and potentially affecting OCT2 activity.

Rifampicin

13292-46-1sc-200910
sc-200910A
sc-200910B
sc-200910C
1 g
5 g
100 g
250 g
$97.00
$328.00
$676.00
$1467.00
6
(1)

Antibiotic impacting OCT2 indirectly by inducing the expression of efflux transporters, such as P-glycoprotein (P-gp), which can alter the disposition of substrates recognized by both P-gp and OCT2.